Leading Brazilian Andrology Clinic to test Felix System
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Memphasys Ltd has announced the commencement of clinical utility testing of the Felix™ System in Brazil, collaborating with Laboratorio Androscience, a leading Brazilian andrology clinic. The testing will benchmark the Felix™ System against existing sperm preparation processes and is expected to run over three months. Memphasys aims to enter the Brazilian IVF market, which is projected to experience significant growth, with potential expansions into Latin America. The company is also engaging with investors interested in supporting its market entry through a licensing arrangement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Memphasys
- Felix Clinical Trial complete, Data Lock expected in 2 weeks
- Publication Highlights Diagnostic Potential of RoXsta TM
- Heranova Felix System Utilisation Testing commences in China
- Bovine Study commences to assess RoXsta antioxidant system
- Felix Clinical Registration Study completed, expanding mkt
Later from Memphasys
- Felix Data lock complete and regulatory submission commenced
- Extension of Convertible Notes
- Half Yearly Report and Accounts
- Felix Trial Confirms Best-in-Class Performance
- RoXsta offers Effective Oxidative Stress Measurem't 4 Cattle
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys